Autopsy report · NCT06191250

--SuPERIOR Trial--

“Study Terminated Prior to trial activation, due to changes in SOC of the treatment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 3 months before it stopped.
• 10 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University Health Network, Toronto

Sponsor type

University, hospital or other

Conditions

Non-Small Cell Lung Cancer (NSCLC); Clinical Staging T2b-3 N0-1 M0

Interventions

Durvalumab; Non-ablative oligofractionated radiation (NORT)

Participants

10

Sites

1

Countries

Canada

Trials that died the same way

• Phase II Study of TAEST16001 in Soft Tissue Sarcoma
  “The study was terminated due to initiation of a new clinical trial with an updated study design.” (73% match in meaning)
• Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
  “Trial terminated due to focus of primary therapeutic areas.” (72% match in meaning)
• A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
  “The study was terminated due to regulatory approval of newer therapeutic options and slower than anticipated accrual.” (70% match in meaning)
• Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
  “The study was terminated due to the sponsor's decision to discontinue the clinical trial.” (70% match in meaning)
• Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
  “Trial terminated because of lack of efficacy in the short term acute phase” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.